Are you someone living with locally advanced or metastatic breast cancer?

If so, consider joining the ELAINE-3 study, a clinical trial for people with metastatic ER+/HER2- breast cancer with an ESR1 mutation investigating a potential new metastatic breast cancer treatment.

Clinical trials help provide patients with new therapies that may work better for them than what is currently available. The ELAINE-3 clinical trial is investigating a targeted endocrine therapy, lasofoxifene, in the treatment of ER+/HER2- metastatic breast cancer. Continue reading to learn more about the study, intervention, and if it may be right for you.

Study Therapies

Metastatic Breast Cancer

About Clinical Research

Who is Elaine?

The ELAINE studies are dedicated in memory of Elaine Davidson Nemzer, MD, the sister of Sermonix co-founder Miriam Davidson Portman, MD. Elaine was a brilliant and compassionate child psychiatrist whose life was cut short by metastatic breast cancer at the age of 47. She was the author of several textbook chapters on psychiatry and a dedicated therapist, teacher, colleague, wife, mother, sister, and friend. Even during her illness, she was a source of comfort and hope to all those she encountered, and her spirit continues to serve as an inspiration to the Sermonix team, filling us with passion and purpose.

Learn more about the ELAINE-3 study

Do you qualify?

You may qualify to participate in the ELAINE-3 study if you:

Are a pre- or postmenopausal woman or man
Have been diagnosed with locally advanced or metastatic ER+/HER- breast cancer with measurable and/or non-measurable lesions
Have radiological or clinical evidence of progression on an Aromatase Inhibitor (AI) in combination with either palbociclib or ribociclib (these are both CDK 4/6 inhibitors) as your first hormonal treatment for metastatic disease
Have been diagnosed with an ESR1 mutation. This may have been detected in previous testing by your doctor and if not, a blood test as part of the study will be done to see if the mutation is present
Have no evidence of progression for at least 6 months on an AI/CDK 4/6 inhibitor combination for advanced breast cancer
Have not progressed on abemaciclib, fulvestrant or other SERD therapy
Have had no more than 1 prior line of chemotherapy in the metastatic setting